Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, announced that it had launched Qdata™ Glaucoma. Qdata Glaucoma is the first-and-only data module reflective of a complete, real-world glaucoma patient journey to accelerate quality insights. The fit-for-purpose data module comprises more than 5 million de-identified patients, ranging from suspect diagnosis through treatment and outcomes. This first-of-its-kind data module is now available for analysis through Verana Health’s real-world evidence service offerings to help life sciences organizations shape glaucoma therapeutic strategies.
Glaucoma Overview
Glaucoma is a group of eye conditions that damage the optic nerve that can cause vision loss and blindness. Often this damage is caused by abnormally high pressure in your eye and is one of the leading causes of blindness for people over the age of 60. It is the second leading cause of blindness worldwide. Anyone can get glaucoma, but certain groups are at higher risk. People with diabetes are two times more likely to get glaucoma than people without diabetes.
According to the National Eye Institute, about 3 million Americans have glaucoma, with an expected 4 million by 2030. Scientists aren’t sure what causes the most common types of glaucoma, but many people with glaucoma have high eye pressure — and treatments that lower eye pressure helps slow the disease. Doctors may advise surgery if glaucoma medicines and laser treatment haven’t helped treat glaucoma. Surgery can’t cure glaucoma or undo vision loss, but it can help protect vision and stop it from getting worse.
In the last decade, we have changed the model of care by virtualizing the practice of medicine where it makes clinical and economic sense. The development of new treatments and surgical options is driving expansion within the glaucoma market – particularly the introduction of new devices. In recent years, the surgical glaucoma treatment landscape has shifted rapidly, moving towards earlier intervention with minimally invasive glaucoma surgery (MIGS) in appropriate patients. The advances in interventions for patients with glaucoma can occur much earlier in the course of their disease. Earlier treatment can slow down and, in some cases, stabilize glaucomatous disease progression and maintain eyesight.
Verana Health Qdata
Qdata™ by Verana Health are disease-specific, fit-for-purpose data modules designed to confidently drive business insights and rigorously inform research outcomes.
Qdata spans three therapeutic areas—ophthalmology, neurology, and urology—and reflects deep patient journeys across robust demographics. Qdata helps unlock quality research insights along with the entire drug and medical device development lifecycle, from the clinical trial sites and subject identification to post-market evidence generation and opportunity analysis.
Verana Health has partnered with the American Academy of Ophthalmology to manage the IRIS Registry, the nation’s first comprehensive eye disease clinical registry and the largest specialty clinical database in medicine. The IRIS Registry contains up to nine years of longitudinal records involving hundreds of millions of patient encounters from more than 15,000 clinicians. VeraQ, Verana Health’s population health data engine, takes detailed IRIS Registry clinical data collected from de-identified patient records and curates the data. Data sets for life sciences analysis are then provided in Qdata, delivering deeper insight on real-world outcomes associated with various MIGS procedures.
Qdata Glaucoma
Qdata Glaucoma—leveraging the IRIS Registry and linked with medical and pharmacy claims—enables insight generation for life sciences organizations using high-quality glaucoma data. The module also delivers the most comprehensive view of the glaucoma patient journey to allow new insights into treatment patterns and outcomes, postmarketing safety, comparative effectiveness, and label expansion and modification.
Qdata Glaucoma is research-ready to power quality insights impacting interventions such as medications and surgical procedures, including minimally invasive glaucoma surgery (MIGS). Qdata Glaucoma can provide insights for:
- Tracking treatment patterns and outcomes via IOP within select cohorts of patients with glaucoma
- Understanding treatment patterns and outcomes for patients who received MIGS procedures
- Conducting postmarketing surveillance via real-world evidence to meet regulatory requirements for a glaucoma medication or medical device to monitor safety and adverse events, as well as understanding patient demographics of early recipients
- Recognizing how a surgery or medication compares to others concerning patient outcomes
- Identify utilization of MIGS procedures in-market to inform regulatory strategy
- Evaluating how a surgery or medication is performing to monitor current sales activity and forecast future sales activity
Qdata Glaucoma uniquely incorporates complete structured and unstructured electronic health record (EHR) data from Ophthalmologists with medical and pharmacy claims from millions of de-identified glaucoma patients treated by more than 15,000 clinicians through Verana Health’s VeraQ™ population health data engine. Verana Health then tokenizes, harmonizes, cleanses, and curates the data with artificial intelligence to provide meaningful insights from glaucoma-specific outcomes and risk factors, such as elevated intraocular pressure (IOP).
Insights using Qdata Glaucoma are now available through Verana Health’s service offerings to life sciences professionals in health economics and outcomes research, medical affairs, market access, and commercialization.
“Life sciences professionals in glaucoma have been burdened by shifting market dynamics across a slew of reimbursement changes, competitor advancements, and issues with treatment adherence that make it difficult to ascertain how to shape their glaucoma therapeutics strategy. Qdata Glaucoma now provides life sciences organizations with unequaled high-quality data and a complete look into the glaucoma patient journey that can guide better business decisions and drive research to inform payer, commercial, and regulatory strategies.” Sujay Jadhav, Chief Executive Officer, Verana Health
About Verana Health
Verana Health is a digital health company committed to delivering quality drug lifecycle and medical practice insights from an exclusive real-world data network. Critical specialty medical societies entrust Verana Health to manage data from more than 20,000 healthcare providers and 70 electronic health record systems. Its healthcare data ecosystem is powered by VeraQ™, a population health data engine that securely powers a data integrity feedback loop of nearly a half-billion point-of-care health encounters. By applying advanced analytics to fit-for-purpose, quality data sets (Qdata™), Verana Health helps life sciences collaborators generate real-world evidence, advance business insights, and accelerate medical innovations that promote quality of care and quality of life.
